Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2015 | Pages:
95 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Partial Seizure - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Partial Seizure - Pipeline Review, H2 2015', provides an overview of the Partial Seizure's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Partial Seizure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Partial Seizure and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Partial Seizure - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Partial Seizure and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Partial Seizure products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Partial Seizure pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Partial Seizure - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Partial Seizure pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Partial Seizure Overview 7 Therapeutics Development 8 Pipeline Products for Partial Seizure - Overview 8 Partial Seizure - Therapeutics under Development by Companies 9 Partial Seizure - Pipeline Products Glance 10 Late Stage Products 10 Clinical Stage Products 11 Early Stage Products 12 Partial Seizure - Products under Development by Companies 13 Partial Seizure - Companies Involved in Therapeutics Development 14 Advicenne Pharma 14 Catalyst Pharmaceutical Partners, Inc. 15 Eisai Co., Ltd. 16 Marinus Pharmaceuticals, Inc. 17 Novartis AG 18 SciFluor Life Sciences, LLC 19 SK Biopharmaceuticals Co., Ltd. 20 UCB S.A. 21 Partial Seizure - Therapeutics Assessment 22 Assessment by Monotherapy Products 22 Assessment by Target 23 Assessment by Mechanism of Action 25 Assessment by Route of Administration 27 Assessment by Molecule Type 29 Drug Profiles 30 brivaracetam - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 clobazam - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 CPP-115 - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 everolimus - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 ganaxolone - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 lacosamide - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 levetiracetam - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 MB-003 - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 perampanel - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 selurampanel - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 SF-0034 - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 YKP-3089 - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 Partial Seizure - Recent Pipeline Updates 59 Partial Seizure - Dormant Projects 82 Partial Seizure - Discontinued Products 83 Partial Seizure - Product Development Milestones 84 Featured News & Press Releases 84 Nov 02, 2015: Eisai Presents Results From Phase III Trial of Antiepileptic Drug Perampanel as Adjunctive Therapy for Refractory Partial-Onset Seizures Conducted in Asia Including Japan 84 Apr 20, 2015: Important UCB presents data on VIMPAT at the 2015 American Academy of Neurology Meeting 85 Jan 05, 2015: Phase III Trial of Antiepileptic Drug Perampanel As Adjunctive Therapy In Patients With Refractory Partial-Onset Seizures Conducted In Asia Including Japan And China Meets Primary Endpoint 87 Dec 08, 2014: UCB announces first presentation of primary data from latest Phase 3 study evaluating brivaracetam as adjunctive treatment of partial-onset seizures in epilepsy 87 Apr 25, 2014: Eisai Presents Research on FYCOMPA (perampanel) CIII at The American Academy of Neurology's 66th Annual Meeting 89 Feb 10, 2014: Fycompa to be Resubmitted Early to German Federal Joint Committee for Additional Benefit Assessment 89 Jan 06, 2014: Eisai Announces Launch of Antiepileptic Drug Fycompa in U.S. 90 Jan 02, 2014: Eisai Announces U.S. Availability of FYCOMPA CIII an Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy Age 12 and Older 91 Nov 20, 2013: New data from UCB's epilepsy portfolio to be highlighted at the 67th Annual Meeting of the American Epilepsy Society 92 Appendix 94 Methodology 94 Coverage 94 Secondary Research 94 Primary Research 94 Expert Panel Validation 94 Contact Us 94 Disclaimer 95
List of Tables
Number of Products under Development for Partial Seizure, H2 2015 8 Number of Products under Development by Companies, H2 2015 9 Comparative Analysis by Late Stage Development, H2 2015 10 Comparative Analysis by Clinical Stage Development, H2 2015 11 Comparative Analysis by Early Stage Development, H2 2015 12 Products under Development by Companies, H2 2015 13 Partial Seizure - Pipeline by Advicenne Pharma, H2 2015 14 Partial Seizure - Pipeline by Catalyst Pharmaceutical Partners, Inc., H2 2015 15 Partial Seizure - Pipeline by Eisai Co., Ltd., H2 2015 16 Partial Seizure - Pipeline by Marinus Pharmaceuticals, Inc., H2 2015 17 Partial Seizure - Pipeline by Novartis AG, H2 2015 18 Partial Seizure - Pipeline by SciFluor Life Sciences, LLC, H2 2015 19 Partial Seizure - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2015 20 Partial Seizure - Pipeline by UCB S.A., H2 2015 21 Assessment by Monotherapy Products, H2 2015 22 Number of Products by Stage and Target, H2 2015 24 Number of Products by Stage and Mechanism of Action, H2 2015 26 Number of Products by Stage and Route of Administration, H2 2015 28 Number of Products by Stage and Molecule Type, H2 2015 29 Partial Seizure Therapeutics - Recent Pipeline Updates, H2 2015 59 Partial Seizure - Dormant Projects, H2 2015 82 Partial Seizure - Discontinued Products, H2 2015 83
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
